Compare MTW & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTW | TECX |
|---|---|---|
| Founded | 1902 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.1M | 549.5M |
| IPO Year | 1994 | N/A |
| Metric | MTW | TECX |
|---|---|---|
| Price | $12.46 | $30.28 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $10.50 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 203.5K | 168.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,240,900,000.00 | N/A |
| Revenue This Year | $4.73 | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.89 | N/A |
| 52 Week Low | $9.09 | $14.39 |
| 52 Week High | $15.56 | $35.99 |
| Indicator | MTW | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 55.69 |
| Support Level | $12.28 | $27.31 |
| Resistance Level | $12.51 | $31.39 |
| Average True Range (ATR) | 0.43 | 1.98 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 80.74 | 61.37 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.